Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

SANTA MONICA, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in redefining how brands connect with consumers through the power ...

Super League Enterprise (SLE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago.

Both flare and persistently active disease (PAD) are common disease activity patterns in patients with systemic lupus erythematosus (SLE). A large prospective multinational cohort study ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...